Bangkok Genomics Innovation PCL (BKK:BKGI) Total Current Assets : ฿209.26 Mil (As of Mar. 2023)

View and export this data going back to 2024. Start your Free Trial

What is Bangkok Genomics Innovation PCL Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Bangkok Genomics Innovation PCL's total current assets for the quarter that ended in Mar. 2023 was ฿209.26 Mil.

Bangkok Genomics Innovation PCL Total Current Assets Historical Data

The historical data trend for Bangkok Genomics Innovation PCL's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bangkok Genomics Innovation PCL Total Current Assets Chart

Bangkok Genomics Innovation PCL Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Total Current Assets

25.31

47.13

136.96

210.39

212.08

Bangkok Genomics Innovation PCL Quarterly Data
	Dec20	Dec21	Mar22	Dec22	Mar23	Dec23
Total Current Assets	Get a 7-Day Free Trial			136.96	-	210.39	209.26	212.08

Bangkok Genomics Innovation PCL Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Bangkok Genomics Innovation PCL's Total Current Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	165.905	+	29.365	+	10.053	+	6.755
	=	212.08

Bangkok Genomics Innovation PCL's Total Current Assets for the quarter that ended in Mar. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	147.545	+	38.526	+	20.086	+	3.106
	=	209.26

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Bangkok Genomics Innovation PCL (BKK:BKGI) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Bangkok Genomics Innovation PCL's Liquidation Value for the quarter that ended in Mar. 2023 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	147.545	-	55.176	+	0.75 * 32.39	+	0.5 * 20.086
=	126.70

Bangkok Genomics Innovation PCL Total Current Assets Related Terms

Thank you for viewing the detailed overview of Bangkok Genomics Innovation PCL's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Bangkok Genomics Innovation PCL (BKK:BKGI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Bangkok Genomics Innovation PCL (BKK:BKGI) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

3689 Rama 4 Road, Phra Khanong Subdistrict, Khlong Toei Subdistrict, Bangkok, THA, 10110

Website

https://www.bangkokgenomics.com

Bangkok Genomics Innovation PCL operate a laboratory and provide medical analysis services. Its services includes Screening for genetic abnormalities in reproductive health (Reproductive Health Testing Services),Infectious Disease Analysis Product Group (Infectious - Related Testing Services), Other screening product groups (Other Testing Services), providing technology services (Tech Solution Services), and Sales of other medical products Related (Medical - Related Products).